Screening for prostate cancer with prostate-specific antigen – an examination of the evidence

New England Journal of Medicine

Volumn 333, Issue 21, 1995, Pages 1401-1405

  Woolf, Steven H ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HORMONE; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SCREENING; CANCER SURVIVAL; CLINICAL TRIAL; CONSERVATIVE TREATMENT; DIAGNOSTIC ACCURACY; EARLY DIAGNOSIS; HUMAN; MALE; PATIENT COUNSELING; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; TREATMENT OUTCOME;

DECISION SUPPORT TECHNIQUES; HUMAN; MALE; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY; SENSITIVITY AND SPECIFICITY;

EID: 0028883394     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199511233332107     Document Type: Review

References (62)

1. Wingo PA, Tong T, Bolden S Cancer statistics, 1995. CA Cancer J Clin 1995; 45: 8-30 [Erratum, CA Cancer J Clin 1995;45:127-8.]
2. Cooner WH, Mosley BR, Rutherford CL Jr, Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. J Urol 1990; 143: 1146-1152
3. Catalona WJ, Smith DS, Ratliff TL, Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991; 324: 1156-1161
4. Catalona WJ, Richie JP, Ahmann FR, Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol 1994; 151: 1283-1290
5. Catalona WJ, Smith DS, Ratliff TL, Basler JW Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 1993; 270: 948-954
6. Mettlin C, Jones G, Averette H, Gusberg SB, Murphy GP Defining and updating the American Cancer Society guidelines for the cancer-related checkup: prostate and endometrial cancers. CA Cancer J Clin 1993; 43: 42-46
7. Preventive Services Task Force. Guide to clinical preventive services. 2nd ed. Baltimore: Williams & Wilkins, 1995.
8. Canadian Task Force on the Periodic Health Examination. The canadian guide to clinical preventive health care. Ottawa, Ont.: Canada Communication Group, 1994.
9. Hicks RJ, Hamm RM, Bemben DA Prostate cancer screening: what family physicians believe is best. Arch Fam Med 1995; 4: 317-322
10. Kramer BS, Brown ML, Prorok PC, Potosky AL, Gohagan JK Prostate cancer screening: what we know and what we need to know. Ann Intern Med 1993; 119: 914-923
11. Ries LAG, Miller BA, Hankey BF, Kosary CL, Harras A, Edwards BK, eds. SEER cancer statistics review, 1973-1991: tables and graphs. Bethesda, Md.: National Cancer Institute, 1994:371. (DHHS publication no. (NIH) 94-2789.)
12. Potosky AL, Miller BA, Albertsen PC, Kramer BS The role of increasing detection in the rising incidence of prostate cancer. JAMA 1995; 273: 548-552
13. Scardino PT Early detection of prostate cancer. Urol Clin North Am 1989; 16: 635-655
14. Sakr WA, Haas GP, Cassin BF, Pontes JE, Crissman JD The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol 1993; 150: 379-385
15. Bureau of the Census. Statistical abstract of the United States, 1993. 113th ed. Washington, D.C.: U.S. Bureau of the Census, 1993.
16. Franks LM Latent carcinoma of the prostate. J Pathol Bacteriol 1954; 68: 603-616
17. Baron E, Angrist A Incidence of occult adenocarcinoma of the prostate. Arch Pathol 1941; 32: 787-793
18. Edwards CN, Steinthorsson E, Nicholson D An autopsy study of latent prostatic cancer. Cancer 1953; 6: 531-554
19. Scott R Jr, Mutchnik DL, Laskowski TZ, Schmalhorst WR Carcinoma of the prostate in elderly men: incidence, growth characteristics and clinical significance. J Urol 1969; 101: 602-607
20. Andrews GS Latent carcinoma of the prostate. J Clin Pathol 1949; 2: 197-208
21. Guileyardo JM, Johnson WD, Welsh RA, Akazaki K, Correa P Prevalence of latent prostate carcinoma in two U.S. populations. J Natl Cancer Inst 1980; 65: 311-316
22. Dhom G Epidemiologic aspects of latent and clinically manifest carcinoma of the prostate. J Cancer Res Clin Oncol 1983; 106: 210-218
23. Oesterling JE Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991; 145: 907-923
24. Sershon PD, Barry MJ, Oesterling JE Serum prostate-specific antigen discriminates weakly between men with benign prostatic hyperplasia and patients with organ-confined prostate cancer. Eur Urol 1994; 25: 281-287
25. Stamey TA, Prestigiacomo A, Komatsu K Physiological variation of serum prostate specific antigen (PSA) from a screening population in the range of 4-10 ng/ml using the Hybritech Tandem-R PSA assay. J Urol 1995; 153: Suppl: 420A-420A abstract.
26. Benson MC, Whang IS, Pantuck A, Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol 1992; 147: 815-816
27. Carter HB, Pearson JD, Metter EJ, Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 1992; 267: 2215-2220
28. Oesterling JE, Jacobsen SJ, Chute CG, Serum prostate-specific antigen in a community-based population of healthy men: establishment of age-specific reference ranges. JAMA 1993; 270: 860-864
29. Stenman UH, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K, Alfthan O A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostate cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991; 51: 222-226
30. Epstein JI, Walsh PC, Carmichael M, Brendler CB Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994; 271: 368-374
31. Mettlin C, Murphy GP, Lee F, Characteristics of prostate cancer detected in the American Cancer Society-National Prostate Cancer Detection Project. J Urol 1994; 152: 1737-1740
32. Halpert B, Schmalhorst WR Carcinoma of the prostate in patients 70 to 79 years old. Cancer 1966; 19: 695-698
33. Friedman GD, Hiatt RA, Quesenberry CP Jr, Selby JV Case-control study of screening for prostatic cancer by digital rectal examinations. Lancet 1991; 337: 1526-1529
34. Gerber GS, Thompson IM, Thisted R, Chodak GW Disease-specific survival following routine prostate cancer screening by digital rectal examination. JAMA 1993; 269: 61-64 [Erratum, JAMA 1993;269:591.]
35. Gohagan JK, Prorok PC, Kramer BS, Cornett JE Prostate cancer screening in the prostate, lung, colorectal and ovarian cancer screening trial of the National Cancer Institute. J Urol 1994; 152: 1905-1909
36. Graversen PH, Nielsen KT, Gasser TC, Corle DK, Madsen PO Radical prostatectomy versus expectant primary treatment in stages I and II prostatic cancer: a fifteen-year follow-up. Urology 1990; 36: 493-498
37. Wilt TJ, Brawer MK The Prostate Cancer Intervention Versus Observation Trial: a randomized trial comparing radical prostatectomy versus expectant management for the treatment of clinically localized prostate cancer. J Urol 1994; 152: 1910-1914
38. Johansson JE Expectant management of early stage prostatic cancer: Swedish experience. J Urol 1994; 152: 1753-1756
39. Walsh PC Using prostate-specific antigen to diagnose prostate cancer: sailing in uncharted waters. Ann Intern Med 1993; 119: 948-949
40. Aus G Prostate cancer: mortality and morbidity after non-curative treatment with aspects on diagnosis and treatment. Scand J Urol Nephrol 1994; 167: Suppl: 1-41
41. Albertsen PC, Fryback DG, Storer BE, Kolon TF, Fine J Long-term survival among men with conservatively treated localized prostate cancer. JAMA 1995; 274: 626-631
42. Wasson JH, Cushman CC, Bruskewitz RC, Littenberg B, Mulley AG Jr, Wennberg JE A structured literature review of treatment for localized prostate cancer. Arch Fam Med 1993; 2: 487-493 [Erratum, Arch Fam Med 1993;2:1030.]
43. Chodak GW, Thisted RA, Gerber GS, Results of conservative management of clinically localized prostate cancer. N Engl J Med 1994; 330: 242-248
44. Catalona WJ Conservative management of prostate cancer. N Engl J Med 1994; 330: 1830-1831
45. Desmond PM, Clark J, Thompson IM, Zeidman EJ, Mueller EJ Morbidity with contemporary prostate biopsy. J Urol 1993; 150: 1425-1426
46. Aus G, Hermansson CG, Hugosson J, Pedersen KV Transrectal ultrasound examination of the prostate: complications and acceptance by patients. Br J Urol 1993; 71: 457-459
47. Fowler FJ Jr, Barry MJ, Lu-Yao G, Roman A, Wasson J, Wennberg JE Patient-reported complications and follow-up treatment following radical prostatectomy: the National Medicare Experience: 1988-1990. Urology 1993; 42: 622-629
48. Office of Technology Assessment. Costs and effectiveness of prostate cancer screening in elderly men. Washington, D.C.: Government Printing Office, 1995. (OTA-BP-H-145.)
49. Mark DH Mortality of patients after radical prostatectomy: analysis of recent Medicare claims. J Urol 1994; 152: 896-898
50. Andriole GL, Smith DS, Rao G, Goodnough L, Catalona WJ Early complications of contemporary anatomical radical retropubic prostatectomy. J Urol 1994; 152: 1858-1860
51. Optenberg SA, Wojcik BE, Thompson IM Morbidity and mortality following radical prostatectomy: a national analysis of Civilian Health and Medical Program of the Uniformed Services beneficiaries. J Urol 1995; 153: 1870-1872
52. Mold JW, Holtgrave DR, Bisonni RS, Marley DS, Wright RA, Spann SJ The evaluation and treatment of men with asymptomatic prostate nodules in primary care: a decision analysis. J Fam Pract 1992; 34: 561-568
53. Krahn MD, Mahoney JE, Eckman MH, Trachtenberg J, Pauker SG, Detsky AS Screening for prostate cancer: a decision analytic view. JAMA 1994; 272: 773-780
54. Catalona WJ Screening for prostate cancer. JAMA 1995; 273: 1174-1174
55. Fleming C, Wasson JH, Albertsen PC, Barry MJ, Wennberg JE A decision analysis of alternative treatment strategies for clinically localized prostate cancer. JAMA 1993; 269: 2650-2658
56. Walsh PC A decision analysis of alternative treatment for clinically localized prostate cancer. J Urol 1993; 150: 1330-1332
57. Beck JR, Kattan MW, Miles BJ A critique of the decision analysis for clinically localized prostate cancer. J Urol 1994; 152: 1894-1899
58. Optenberg SA, Thompson IM Economics of screening for carcinoma of the prostate. Urol Clin North Am 1990; 17: 719-737
59. Rosen MA Analysis of the annual cost of a fully implemented prostate cancer screening program. J Urol 1995; 153: Suppl: 464A-464A abstract.
60. Littrup PJ, Goodman AC, Mettlin CJ The benefit and cost of prostate cancer early detection. CA Cancer J Clin 1993; 43: 134-149
61. Hahn DL, Roberts RG PSA screening for asymptomatic prostate cancer: truth in advertising. J Fam Pract 1993; 37: 432-436
62. The PSA decision: what you need to know. Hanover, N.H.: Foundation for Informed Medical Decision Making, 1994 (videotape).